Summary The purpose of this study was to determine the effect of the first rat monoclonal antibody (MAb ICR62) to the epidermal growth factor receptor (EGFR) in a phase I clinical trial in patients with unresectable squamous cell carcinomas. This antibody effectively blocks the binding of EGF, transforming growth factor (TGF)-oc and HB-EGF to the EGFR, inhibits the growth in vitro of tumour cell lines which overexpress the EGFR and eradicates such tumours when grown as xenografts in athymic mice. Eleven patients with squamous cell carcinoma of the head and neck and nine patients with squamous cell carcinoma of the lung, whose tumours expressed EGFR, were recruited. Groups of three patients were treated with 2.5 mg, 10 mg, 20 mg or 40 mg of ICR62 and a further eight patients received 100 mg. All patients were evaluated for toxicity using WHO criteria. Patients' sera were tested for the clearance of MAb ICR62 and the development of human antirat antibodies (HARA). No serious (WHO Grade III-IV) toxicity was observed in patients treated with up to 100 mg of antibody ICR62. Antibody ICR62 could be detected at 4 h and 24 h in the sera of patients treated with 40 mg or 100 mg of ICR62. Only 4/20 patients showed HARA responses (one at 20 mg, one at 40 mg and two at 100 mg doses) and of these only the former two were anti-idiotypic responses. In four patients receiving doses of ICR62 at 40 mg or greater, biopsies were obtained from metastatic lesions 24 h later and examined for the localisation of ICR62 using anti-rat antibody reagent. In these patients we showed the localisation of MAb ICR62 to the membranes of tumour cells; this appeared to be more prominent at the higher dose of 100 mg. On the basis of these data we conclude that MAb ICR62 can be administered safely to patients with squamous cell carcinomas and that it can localise efficiently to metastases even at relatively low doses.
It is becoming increasingly evident that alterations in the level of expression of growth factors and their receptors may play an important role in the pathogenesis of human malignancies (Goustin et al., 1986; Aaronson, 1991; Cross and Dexter, 1991; Waterfield, 1991; Pusztai et al., 1993; Mendelsohn and Lippman, 1993; Nicolson, 1993) . Of the systems studied, it is clear that the aberrant expression of the epidermal growth factor (EGF) receptor system is particularly important in the development of certain types of human malignancy (Thompson and Gill, 1985; Ozanne et al., 1986; Gullick, 1991; Harris, 1994; . The human EGF receptor is a 170 kDa transmembrane tyrosine kinase that transmits the mitogenic actions of the EGF family of ligands. This includes EGF, transforming growth factor (TGF)-a, amphiregulin, HB-EGF, and betacellulin (Cohen, 1962; Todaro et al., 1976; Das et al., 1977; Shoyab et al., 1989; Higashiyama et al., 1991; Shing et al., 1993; Carpenter, 1987) .
Overexpression of the EGFR accompanied by production of one or more of its ligands has been reported in a wide range of human malignancies, including cancer of the bladder, brain, head and neck, pancreas, lung, breast and ovary (Cowley et al., 1984; Ozanne et al., 1986; Neal et al., 1990; Gullick, 1991; ). This in turn has been associated with poor survival in many of these patients (for review see . Recent studies have also indicated that the growth of tumours overexpressing the EGF receptor can be stimulated by its ligands in several ways, e.g. via autocrine, paracrine or juxtacrine modes (Sporn and Roberts, 1985; Derynck, 1992; . However, since the ligandinduced activation of these cells occurs primarily via receptors on the cell surface rather than intracellularly, this system may form a suitable target for monoclonal antibodydirected therapy (Van de Vijvert et al., 1991; Baselga and Mendelsohn, 1994; .
We have reported recently the production and characterisation of a number of rat MAbs directed against the extracellular domain of the EGFR using as immunogens the human head and neck tumour cell line HN5, breast carcinoma cell line MDA-MB 468 or the vulval carcinoma cell line A431, all of which overexpress the human EGFR (see for details). Our aim was to obtain a diverse population of antibodies that bound to distinct epitopes on the EGFR and which were of different isotype in order to select the best MAb or combination of MAbs for therapeutic and diagnostic use. Of these, the IgG2b MAb ICR62 was prominent in that it (a) effectively blocks the binding of EGF, TGF-ai, and HB-EGF to EGFR; (b) inhibits the growth of EGFR-overexpressing tumour cell lines in vitro (Modjtahedi et al., 1993a; ; and (c) was the most effective antibody in our MAb library for eradicating such tumours in athymic mice (Modjtahedi et al., 1993b; Dean et al., 1994) . We have also reported recently that antibodies to the EGFR that inhibit the growth of EGFR-overexpressing tumours do so by inducing terminal differentiation and that a further therapeutic effect may be obtained via immunological mechanisms with rat IgG2b MAbs such as ICR62 .
For these reasons we have selected MAb ICR62 for a phase I clinical study in patients with unresectable squamous cell carcinoma of the head and neck or lung. These tumour types commonly overexpress the EGFR. With only limited quantities of antibody available, the aims of this initial study were to (a) monitor the toxicity of ICR62 in the dose range of 2.5-100 mg, (b) investigate the localisation of MAb ICR62 to tumour cells in metastatic lesions, (c) determine the dose of ICR62 necessary to achieve circulating ICR62 in the blood and (d) assay for human anti-rat antibody (HARA) (Table  I ). All patients were evaluated for toxicity using standard WHO criteria. Blood samples were taken before and at intervals after dosing with ICR62 so that levels of MAb ICR62 in circulation could be measured and sera tested for the presence of HARA. In six patients given antibody doses of 40 mg or 100 mg, biopsies were taken from accessible metastatic lesions 24 h following dosing and examined for the localisation of ICR62. To assay for the localisation of MAb ICR62 to tumours in patients, biopsies were taken from an accessible metastatic site 24 h after antibody dosing. Serial sections were cut and stained with secondary antibody alone or ICR62 followed by the secondary antibody. This technique enabled us to determine the proportion of EGFRexpressing cells that had bound administered ICR62 (Table I) . Symptoms were controlled by hydrocortisone (100 mg) and Piriton (10 mg). In no case were any severe toxicities (Grade III -IV) observed. None of the patients reported any untoward effects of their treatment during the follow-up period.
Serum levels of ICR62
No free antibody was detected in the sera, sampled at 4 h or 24 h post dosing, of patients given 20 mg or less of ICR62 (Figure la) . However, MAb ICR62 could be detected in the sera of patients following doses of 40 mg or 100 mg ( Figure  lb and lc). In addition, the level of ICR62 remaining in circulation was found to be highest in the patients receiving 100 mg of ICR62 (Figure 1) . In one such patient (number 13), MAb Figure 2a show that 24 h after treatment of patient 12 with 40 mg of ICR62, the antibody had localised to the membranes of tumour cells around the periphery of the epithelial cell islands in the metastatic site. When a sequential section was stained with ICR62 before the addition of the sheep anti-rat reagent, it was found that all cells, including those in the interior of the epithelial cell islands expressed the EGFR (Figure 2b ). However, when frozen sections of biopsies obtained from metastases of patients treated with 100 mg of ICR62 were examined, it was clear that the MAb had penetrated further into the epithelial component of the metastatic lesions with a greater proportion of EGFR-positive cells having bound administered ICR62 (e.g. Figures 3a and 3c  or 3b and 3d) .
Development of human antibodies to ICR62
Of the 20 patients treated with ICR62, HARA were detected in the sera of four patients (numbers 9, 11, 16 and 19; see Table I ). Of these, only two patients given 20 mg (no. 9) or 40 mg (no. 11) produced anti-idiotypic antibodies that bound to scFv ICR62 (Figure 4) . Sera from two out of eight patients treated with 100 mg of ICR62 (patients 16 and 19) contained antibodies directed against determinants on the constant region since they bound to the Fab fragment and intact antibody but not to the ICR62 scFv (Table I, Figure 5 ). In one patient (no. 12), the results obtained with the serum taken before treatment indicated that antibodies that bound to rat IgG were present in the sera before ICR62 was administered. It is unknown whether binding was specific or due to the presence of cross-reactive autoantibodies.
Discussion
Overexpression of the EGFR accompanied by production of the EGF family of ligands has been found to occur in a wide range of human malignancies and this phenomenon has been correlated with a poorer prognosis in these patients (for review see Gullick, 1991; Dilution of patient serum Figure 4 Development of human anti-rat antibodies in the serum of patient number 9 following injection of 20 mg ICR62 shown by binding to intact ICR62 (a), Fab ICR62 (b) and scFv ICR62 (c). This indicates an anti-idiotypic specificity, * Prebleed; 1, dayl4; *, day 28.
but also for diagnostic and therapeutic applications in cancer (for review see . Several of the mouse antibodies have undergone clinical evaluation in phase I and phase II studies in patients with head and neck, lung or brain cancers including MAb EGFR1 (Soo et al., 1987; Kalofonos et al., 1989), MAbs 225 and 528 (Divigi et al., 1991; Baselga et al., 1993 ), MAb 425 (EMD 55900 E Merck, Brady et al., 1991 Magdelenat et al., 1991; Stasiecki et al., 1993; Blizer et al., 1993; Dadparvar et al., 1994) and MAb RG83852 (Perez-Soler et al., 1994) . The aim of these studies, in common with the one presented here, was to determine whether treatment of cancer patients with anti-EGFR MAbs produced life-threatening toxicities by their binding to EGFR expressed by normal tissues, including liver and skin. The results of these studies have shown that mouse antibodies to the EGFR can be given safely to patients without untoward toxicity. For example, Divigi et al. (1991) rat MAbs we had generated against the human EGFR at inducing the regression of xenografts of head and neck, vulva and breast carcinomas grown in athymic mice (Modjtahedi et al., 1993b Dean et al., 1994) . In the present study, the results of the immunohistological investigation showed that the cells adjacent to the vasculature were strongly stained. This tumour cell population is likely to have the highest proliferation index and any antiproliferative/ pro-differentiation effect here may be therapeutically significant. This study has shown that MAb ICR62 can be given safely to cancer patients at doses up to 100 mg producing only mild toxicity. This trial was not designed to test the antitumour activity of this agent.
The maintainance of receptor blockade may require repeated treatment with antibody. Certainly, our experience using xenograft models (Modjtahedi et al., 1993b points to the need to maintain sufficiently high blood levels for long enough to (a) block EGFR function, (b) 
